2011 ASH Annual Meeting Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia. December 12, 2011
|
|
- Alaina Butler
- 5 years ago
- Views:
Transcription
1 211 ASH Annual Meeting Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia December 12, 211
2 Hepcidin is Central Regulator of Iron Homeostasis Hepcidin is liver-expressed, secreted peptide hormone that regulates iron Hepcidin exerts action through regulation of ferroportin» Binds ferroportin, causing ubiquitination, internalization, and degradation in lysosomes Ferroportin is only known cellular iron exporter in vertebrates» Found on hepatocytes, macrophages, and enterocytes Nemeth, Adv Hematol., 21 Fpn = Ferroportin Fe-Tf = Transferrin-bound iron Hepcidin Fpn Dietary Fe Absorption Fe Release from Cellular Stores Plasma Fe-Tf 2
3 Anemia of Chronic Disease (ACD) and Hepcidin ACD often diagnosed in 3 settings, each associated with elevated serum hepcidin levels» Chronic kidney disease» Cancer» Chronic inflammatory states (e.g. rheumatoid arthritis) Currently managed with ESAs and IV iron to achieve target Hb levels Inappropriately elevated hepcidin results in impaired mobilization of iron needed for efficient erythropoiesis serum hepcidin (ng/ml) NL CRP MM ACKD PCKD IDA n = Ganz et al., Blood 28 CRP = CRP >1 mg/dl (1x upper normal) MM = multiple myeloma ACKD/PKCD = adult/pediatric CKD, noninflammatory IDA = iron deficiency anemia Targeting the hepcidin pathway represents a novel, physiological, and potentially safer approach to managing ACD 3
4 RNA Interference (RNAi) A New Class of Innovative Medicines RNAi Therapeutics Harness natural pathway» Catalytic mechanism» Mediated by small interfering RNAs or s Treat disease with therapeutic gene silencing» Any gene in genome Major breakthroughs in delivery achieved» Includes systemic RNAi with formulations and chemistries» Enable advancement of RNAi products to clinic and market 4
5 Hepcidin Liver mrna Level Serum Iron (ug/dl) ALN-HPN Pre-Clinical Efficacy Silencing Hepcidin Increases Serum Iron Silencing hepcidin (HAMP1) mrna increases serum iron in mouse model >8% silencing of liver hepcidin mrna after single dose Results in ~2-fold increase in serum iron levels Phenocopies genetics HAMP1 mrna Serum Iron ANOVA, Dunnet s t post-hoc, compared to Control * p <.5, *** p <.1 TIBC *** *** PBS Control Hepcidin PBS Control Hepcidin C57BL6 mice, 48 hr post-administration, mean ± sd 5
6 AVG Animal 1 Animal 2 Animal 3 AVG Relative Liver HAMP mrna (% Control) Serum Hepcidin (mg/ml) Serum Iron (ug/dl) Proof of Concept in Nonhuman Primates Animals: male cynomolgus monkeys Dose: 1 mg/kg of LNP-formulated HAMP-targeting via 15 min IV infusion Liver HAMP mrna (48 h) mean ± sd 4 3 Serum Hepcidin Protein Animal 1 Animal 2 Animal Serum Iron Day -9 Day -6 Day h 48 h 1 5 Animal 1 Animal 2 Animal 3 Day -9 Day -6 Day h 48 h Pre-Dose Post-Dose Pre-Dose Post-Dose Control Samples Treated Samples Single administration of LNP- leads to rapid reduction of hepcidin mrna and protein, resulting in elevation of serum iron levels in NHPs 6
7 Exploring Additional Targets in Hepcidin Pathway Rationale Number of additional targets have human genetic validation» HFE: HH type 1» HJV: HH type 2A» TFR2: HH type 3 Use RNAi technology to improve our understanding of hepcidin signaling pathway Targets HJV, TFR2, HFE, BMPRI, BMPRII, BMP6, Neogenin, IL6R, SMAD4 Pietrangelo, J Heptatology, 21. 7
8 HAMP1 Liver mrna Level (% of PBS) TFsat (%) TFR2 Liver mrna Level (% of PBS) 15 TFR2 Silencing TFR2 is Attractive Hepcidin Pathway Target And Increases Transferrin Saturation 2 PBS Control TFR2 Results in HAMP1 Silencing PBS Control TFR2 PBS Control TFR2 C57BL6 mice, 48 hr post-administration, mean ± sd 8
9 HAMP1 Liver mrna (% of PBS) TFsat (%) TFR2 Liver mrna (% of PBS) 12 TFR2 Targeting Results in Sustained Elevation of TFR2 Silencing Transferrin Saturation Time (day) Results in HAMP1 Silencing Time (day) And Increases Transferrin Saturation Time (day) C57BL6 mice, single IV.3 mg/kg dose, mean ± sd
10 Serum Iron (ug/dl) Hb (g/dl) TFR2 Liver mrna Level (% of Control) HAMP Liver mrna Level (% of Control) 1 Efficacy in a Rat Anemia of Chronic Disease Model Model* Lewis rats, male Initiation with single IP injection of PG-APS (polymers form Group A Streptococci) Treat 3X weekly starting D21 Measure serum and hematology parameters biweekly and at 48 hr post final treatment Liver mrna measurement 48 hr post final treatment Results Effective silencing of TFR2 and HAMP mrna Approximately 2X increase in serum iron upon treatment Increase in Hb to g/dl with treatment *following Coccia et al., Exp Hematology, TFR2 mrna - - Control Saline PG-APS Serum Iron TFR2 PG-APS PG-APS+Cont PG-APS+TFR inj inj Day inj mean ± sd HAMP mrna - - Control TFR2 Saline PG-APS Hemoglobin PG-APS PG-APS+Cont PG-APS+TFR inj inj Day inj
11 Summary ACD represents area of unmet need and hepcidin thought to play an important role in disease pathology Using RNAi to target hepcidin pathway represents novel, physiological, and potentially safer approach to managing ACD Silencing of hepcidin has been achieved in rodents and NHPs using, resulting in concomitant increases in serum iron Evaluation of hepcidin pathway reveals TFR2 as particularly attractive target for RNAi TFR2 silencing leads to potent and durable reduction in hepcidin, persistent elevation in serum iron, and amelioration of anemia in rodent model of ACD 11
Discovery. Hepcidin Today. Hepcidin: discovery June 2000: Man: Plasma ultrafiltrate Liver Expressed Antimicrobial Peptide
Hepcidin Today Rachel van Swelm 10 05 2018 ISLH www.radboud ironcenter.com; www.hepcidinanalysis.com Discovery Hepcidin: discovery June 2000: Man: Plasma ultrafiltrate Liver Expressed Antimicrobial Peptide
More informationBMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice
SUPPLEMENTARY MATERIALS BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice Elena Corradini, Paul J. Schmidt, Delphine Meynard, Cinzia Garuti, Giuliana
More informationPCSK9 RNAi Therapeutics. Kevin FitzGerald
PCSK9 RNAi Therapeutics Kevin FitzGerald Presenter Disclosure Information PSCK9 RNAi Therapeutics The following relationships exist related to this presentation:» Kevin Fitzgerald and Alnylam team members:
More informationIntroduction 5/2/2013 IRON RELATED GENES AND OXIDATIVE STRESS IN NON- ALCOHOLIC STEATOHEPATITIS. Iron Physiology. Iron Physiology
// IRON RELATED GENES AND OXIDATIVE STRESS IN NON- ALCOHOLIC STEATOHEPATITIS DIANA MOYA, MD PEDIATRIC GASTROENTEROLOGY FELLOW DIGESTIVE DISEASES & NUTRITION CENTER MAY,. Iron Physiology. /NAFLD. Iron Metabolism
More informationIn Focus - Micronutrients and Obesity: iron deficiency & obesity.
In Focus - Micronutrients and Obesity: iron deficiency & obesity. Ana Carla Cepeda López MD PhD Universidad de Monterrey, Vicerrectoría de Ciencias de la Salud, Departamento de Ciencias Básicas. Monterrey,
More informationIron: a global issue in hematology. Clara Camaschella, MD
Iron: a global issue in hematology Clara Camaschella, MD Università Vita Salute San Raffaele e IRCCS San Raffaele - Milano Firenze, 18-19 settembre 2015 Clara Camaschella I have nothing to disclose Iron
More informationRole of Serum Hepcidin levels in the Diagnosis of Iron Deficiency Anemia in Children in Saudi Arabia
Role of Serum Hepcidin levels in the Diagnosis of Iron Deficiency Anemia in Children in Saudi Arabia Mahmoud Mohamed Elgari*, Al-Oufi F¹, Mohammed alsalmi, M. Kurdi, NA Ibrahim, Abdelgadir Elmugadam College
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol. 69 (8), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol. 69 (8), Page 2997-3002 Anemia of Chronic Disease Ayman Ali Alhboob 1, Khuludyahyam.Khati 2, SAMAHER Sahal Malibari 3, Bariahyahya Drain 4,
More informationFourth European Symposium on Rare Anaemias. Vita-Salute University - San Raffaele Scientific Institute, Milano
Fourth European Symposium on Rare Anaemias Clara Camaschella Vita-Salute University - San Raffaele Scientific Institute, Milano Sofia, Bulgaria, November 19-20, 2011 The iron cycle Hepcidin (Jordan et
More informationLaboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth
Laboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth Why does it matter? Over 30% of the Worlds population are anaemic,
More informationAnemia 1: Fourth year Medical Students/ Feb/22/ Abdallah Awidi Abbadi.MD.FRCP.FRCPath Professor
Anemia 1: Fourth year Medical Students/ Feb/22/ 2018 Abdallah Awidi Abbadi.MD.FRCP.FRCPath Professor Email: abdalla.awidi@gmail.com Kidney EPO O2 Sensor Blood vessel Definition: Anemia is operationally
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationTHE ROLE OF HEMOJUVELIN IN IRON DEFICIENCY AND OVERLOAD
THE ROLE OF HEMOJUVELIN IN IRON DEFICIENCY AND OVERLOAD Clara Camaschella Vita-Salute University and San Raffaele Scientific Institute Milan, Italy EHA ESH joint Workshop Cascais, Portugal, April 16-18,
More informationThe problem with pumping too much iron
The problem with pumping too much iron Stephen D. Zucker, M.D. Professor of Medicine Director of Hepatology Disclosures NONE* * Would be pleased to entertain any reasonable offer Brief History of Hemochromatosis
More informationMetabolismo del ferro in condizioni normali e patologiche
Metabolismo del ferro in condizioni normali e patologiche Clara Camaschella Università Vita-Salute e IRCCS San Raffaele, Milano Simposio SIES 41 Congresso Nazionale SIE - Bologna 14-17 ottobre 2007 Metabolismo
More informationIron age: novel targets for iron overload
IRON HOMEOSTASIS &CHRONIC DISEASE:DISORDERS OF IRON OVERLOAD Iron age: novel targets for iron overload Carla Casu 1 and Stefano Rivella 1,2 1 Department of Pediatrics, Division of Hematology-Oncology,
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationAsiaTIDES 2012: Formulation and Delivery of Peptides and Oligonucleotides Strategies for Delivery of RNAi Therapeutics. March 1, 2012 Akin Akinc, PhD
AsiaTIDES 2012: Formulation and Delivery of Peptides and Oligonucleotides Strategies for Delivery of RNAi Therapeutics March 1, 2012 Akin Akinc, PhD Lead Selection Alnylam RNAi Product Platform Turning
More informationBiochimica et Biophysica Acta
Biochimica et Biophysica Acta 1823 (2012) 1434 1443 Contents lists available at SciVerse ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbamcr Review Hepcidin and
More informationStudy of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents
Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents Prof. Azza Abdel Shaheed Prof. of Child Health NRC National Research Centre Egypt Prevalence of childhood
More informationIron and hepcidin: a story of recycling and balance
Iron and hepcidin: a story of recycling and balance Domenico Girelli (Medicina Generale a indirizzo Immuno-Ematologico e Emocoagulativo, Azienda Ospedaliera Universitaria Integrata VERONA) Special Conference
More informationJournal of American Science 2018;14(10)
Hepcidin Level and Iron Status in End Stage Renal Disease (ESRD) Patients Tarek El Baz 1, Fawzy Hamed 1, Amr Mohab 3, Abdallah Mahmoud, Magdy El-Said 1, Osama Khamis 1, Amgad Awad 1, Haytham Sabry 1 and
More informationSupplementary Figure 1. Repression of hepcidin expression in the liver of mice treated with
Supplementary Figure 1. Repression of hepcidin expression in the liver of mice treated with DMN Immunohistochemistry for hepcidin and H&E staining (left). qrt-pcr assays for hepcidin in the liver (right).
More informationOral Iron Safe, Effective, and Misunderstood Duke Debates 2017
Oral Iron Safe, Effective, and Misunderstood Duke Debates 2017 John Strouse, MD, PhD Instructor (temp) Medicine and Pediatrics Director, Adult Sickle Cell Program April 20, 2017 1 Disclosures I have no
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More information2013 OTS Annual Meeting Pre-clinical Development of ALN-AS1 RNAi Therapeutic for the Treatment of Acute Intermittent Porphyria.
2013 OTS Annual Meeting Pre-clinical Development of ALN-AS1 RNAi Therapeutic for the Treatment of Acute Intermittent Porphyria October 8, 2013 Acute Intermittent Porphyria (AIP) Program Unmet Need and
More informationRole of hepcidin in the pathophysiology and diagnosis of anemia
BLOOD RESEARCH VOLUME 48 ㆍ NUMBER 1 March 2013 REVIEW ARTICLE Role of hepcidin in the pathophysiology and diagnosis of anemia Guido D Angelo Ematologia/Coagulazione, Laboratorio di Chimica-Clinica, Ematologia
More informationSYSTEMIC IRON REGULATION AND ADIPOSE TISSUE INFLAMMATION IN HEALTH AND DISEASE. Xiaoya Ma
SYSTEMIC IRON REGULATION AND ADIPOSE TISSUE INFLAMMATION IN HEALTH AND DISEASE by Xiaoya Ma A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Kinesiology)
More informationSupplementary Information: Figures 1-6 and Table 1 RNAi-Mediated Gene Silencing in Non-Human Primate Zimmermann, T.S. et al.
Supplementary Information: Figures 1-6 and Table 1 RNAi-Mediated Gene Silencing in Non-Human Primate Zimmermann, T.S. et al. a. 12 14 Relative apob mrna (%) 8 6 4 2 Relative apob mrna (%) 12 8 6 4 2 5
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia The Harvard community
More informationHereditary Hemochromatosis: What Have We Learnt from Population Studies Professor John K. Olynyk
Hereditary Hemochromatosis: What Have We Learnt from Population Studies School of Medicine & Pharmacology University of Western Australia & Department of Gastroenterology Fremantle Hospital 1 The amount
More informationClinical Study Serum Hepcidin Levels and Reticulocyte Hemoglobin Concentrations as Indicators of the Iron Status of Peritoneal Dialysis Patients
International Nephrology Volume 2012, Article ID 239476, 7 pages doi:10.1155/2012/239476 Clinical Study Serum Hepcidin Levels and Reticulocyte Hemoglobin Concentrations as Indicators of the Iron Status
More informationA Broad Clinical Pipeline of Innovative Diabetes / Renal & Oncology Programs. European Business Development Conference Düsseldorf 24 Sept 2013
A Broad Clinical Pipeline of Innovative Diabetes / Renal & Oncology Programs European Business Development Conference Düsseldorf 24 Sept 2013 Key facts about NOXXON Developing a new class of proprietary
More informationNuovi Approcci alla Ferrochelazione
Il Deficit di PKD 1 patient day Nuovi Approcci alla rrochelazione M. Domenica Cappellini Fondazione Ca Granda Policlinico Università di Milano Milano May 16 2015 Genetic and acquired iron overload Genetic
More informationMicrocytic Hypochromic Anemia An Approach to Diagnosis
Microcytic Hypochromic Anemia An Approach to Diagnosis Decreased hemoglobin synthesis gives rise to microcytic hypochromic anemias. Hypochromic anemias are characterized by normal cellular proliferation
More informationALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results
ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results Kevin Fitzgerald, PhD Co-authors: Amy Simon 1, Suellen White 1,
More information3) The sheer number of and inconsistency between different animal models used make the paper difficult to follow and may impact data interpretation:
Reviewers' comments: Reviewer #1 (Remarks to the Author): In this manuscript, Pasricha et al. show that iron deficiency (ID) and stimulated erythropoiesis suppress hepcidin via distinct processes. They
More informationSystemic iron homeostasis is dependent on the hepatic
LIVER BIOLOGY/PATHOBIOLOGY Evidence for Distinct Pathways of Hepcidin Regulation by Acute and Chronic Iron Loading in Mice Emilio Ramos, 1 Léon Kautz, 4,5 Richard Rodriguez, 2 Michael Hansen, 2 Victoria
More informationComorbidities in Heart Failure: Iron Deficiency. Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah
Comorbidities in Heart Failure: Iron Deficiency Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah ACC Middle East Conference 2018 Iron Deficiency in Heart Failure
More informationAnemia in the elderly. Nattiya Teawtrakul MD., PhD
Anemia in the elderly Nattiya Teawtrakul MD., PhD Contents Definition of anemia in the elderly The impact of anemia in the elderly Etiology of anemia in the elderly Management of anemia in the elderly
More informationIron-Sensing Proteins that Regulate Hepcidin and Enteric Iron Absorption
Annu. Rev. Nutr. 2010. 30:149 71 First published online as a Review in Advance on April 20, 2010 The Annual Review of Nutrition is online at nutr.annualreviews.org This article s doi: 10.1146/annurev.nutr.012809.104801
More informationBMP6 Treatment Compensates for the Molecular Defect and Ameliorates Hemochromatosis in Hfe Knockout Mice
GASTROENTEROLOGY 2010;139:1721 1729 BMP6 Treatment Compensates for the Molecular Defect and Ameliorates Hemochromatosis in Hfe Knockout Mice ELENA CORRADINI,*, PAUL J. SCHMIDT, DELPHINE MEYNARD,* CINZIA
More informationManaging peri-operative anaemiathe Papworth way. Dr Andrew A Klein Royal Papworth Hospital Cambridge UK
Managing peri-operative anaemiathe Papworth way Dr Andrew A Klein Royal Papworth Hospital Cambridge UK Conflicts of interest: Unrestricted educational grants/honoraria from CSL Behring, Brightwake Ltd,
More informationCOORDINATION OF IRON AND OXYGEN SIGNALING THROUGH POST- TRANSCRIPTIONAL REGULATION OF HYPOXIA INDUCIBLE FACTOR-2ALPHA MCKALE R.
COORDINATION OF IRON AND OXYGEN SIGNALING THROUGH POST- TRANSCRIPTIONAL REGULATION OF HYPOXIA INDUCIBLE FACTOR-2ALPHA By MCKALE R. DAVIS Bachelor of Science in Nutrition and Dietetics Texas Christian University
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationUnraveling Mechanisms Regulating Systemic Iron Homeostasis
UPDATES ON DISORDERS OF IRON UTILIZATION AND DISTRIBUTION Unraveling Mechanisms Regulating Systemic Iron Homeostasis Karin E. Finberg 1 1 Duke University Medical School, Durham, NC Systemic iron balance
More informationManaging Anaemia in IBD
Oxford Inflammatory Bowel Disease & Hepatology MasterClass Managing Anaemia in IBD Dr Alex Kent Senior Research Fellow Disclosures WHO Classification of Anaemia Normal haemoglobin and haematocrit levels
More informationThe Interaction of Alcohol and Iron-Overload in the in-vivo Regulation of Iron Responsive Genes
Cantaurus, Vol. 5, -, May 7 McPherson College Division of Science and Technology The Interaction of Alcohol and Iron-Overload in the in-vivo Regulation of Iron Responsive Genes Callie Crist, Elizabeth
More informationModulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance
Related Commentary, page 1755 Research article Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance Jodie L. Babitt, 1 Franklin W. Huang, 2 Yin Xia, 1 Yisrael Sidis,
More informationReview Article Crosstalk between Iron Metabolism and Erythropoiesis
Advances in Hematology Volume 2010, Article ID 605435, 12 pages doi:10.1155/2010/605435 Review Article Crosstalk between Iron Metabolism and Erythropoiesis Huihui Li and Yelena Z. Ginzburg Lindsley F.
More informationBMP6 and BMP4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-hjv
BMP6 and BMP4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-hjv Y.J. Shi and X.T. Pan Affiliated Taicang Hospital of Suzhou University, Taicang, Jiangsu, China
More informationAnemia and Iron Deficiency: What Every Cardiologist Needs to Know
6th Saudi HF Group Symposium Riyadh - December 8-9, 2017 Anemia and Iron Deficiency: What Every Cardiologist Needs to Know Ammar Chaudhary MBChB, FRCPC Consultant Cardiologist Advanced Heart Failure Department
More informationIron Status in Type 2 Diabetes Patients With and Without Metabolic Syndrome
Original Article Iron Status in Type 2 Diabetes Patients With and Without Metabolic Syndrome Sanda Kyaw*, Hnin Oo Pwint**, Myat Thandar, Mya Thandar Sein, Cho Cho Aung*, Ohnmar* Abstract Elevated serum
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationDevelopment of an RNA Interference Therapeutic Targeting Angiopoietin-Like Protein 3 for Treatment of Hyperlipidemia
Development of an RNA Interference Therapeutic Targeting Angiopoietin-Like Protein 3 for Treatment of Hyperlipidemia November 12 th, 2018 So C. Wong Arrowhead Pharmaceuticals Inc. Disclosures All authors
More informationHHS Public Access Author manuscript Ann N Y Acad Sci. Author manuscript; available in PMC 2017 March 01.
New strategies to target iron metabolism for the treatment of beta thalassemia Paraskevi Rea Oikonomidou 1, Carla Casu 1, and Stefano Rivella 1,2 1 Department of Pediatrics, Division of Hematology, Children
More informationMass spectrometry-based serum Protein Profiling. at population level: serum hepcidin and beyond
UNIVERSITA DEGLI STUDI DI MILANO-BICOCCA FACOLTA DI MEDICINA E CHIRURGIA DOTTORATO DI RICERCA IN EMATOLOGIA SPERIMENTALE (XXV ciclo) Coordinatore: Prof. Carlo Gambacorti Passerini TESI DI DOTTORATO DI
More informationAssessing Iron Deficiency in Adults. Chris Theberge. Iron (Fe) deficiency remains as one of the major global public health problems for
Assessing Iron Deficiency in Adults Chris Theberge Iron (Fe) deficiency remains as one of the major global public health problems for two reasons. It affects about one fourth of the world s population
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationHYPOXIA-DEPENDENT HEPCIDIN DOWN-REGULATION: IN VITRO AND IN VIVO STUDIES
University of Milano-Bicocca School of Medicine and Surgery PhD in Experimental Hematology, XXVII cycle HYPOXIA-DEPENDENT HEPCIDIN DOWN-REGULATION: IN VITRO AND IN VIVO STUDIES Dr. Giulia Ravasi Coordinator:
More informationMECHANISMS OF NON-TRANSFERRIN-BOUND IRON UPTAKE BY HUMAN β CELLS AND THE ROLE OF IRON IN DIABETIC PATHOGENESIS
MECHANISMS OF NON-TRANSFERRIN-BOUND IRON UPTAKE BY HUMAN β CELLS AND THE ROLE OF IRON IN DIABETIC PATHOGENESIS By RICHARD COFFEY A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA
More informationInto the matrix: regulation of the iron regulatory hormone hepcidin by matriptase-2
Emerging Science Into the matrix: regulation of the iron regulatory hormone hepcidin by matriptase-2 Mitchell D Knutson Matriptase-2 is a recently identified membrane-bound, cell-surface serine protease
More information27/01/2019. Anaemia, Transfusion and TACO Lise Estcourt. Anaemia. What is anaemia?
Anaemia, Transfusion and TACO Lise Estcourt 1 Anaemia 2 What is anaemia? 3 1 Anaemia according to WHO 4 Anaemia in palliative care Common (77% men 68% women) Symptoms often non-specific Some causes potentially
More informationIron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016
Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationClinical Policy: Iron Sucrose (Venofer) Reference Number: CP.PHAR.167
Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 03/16 Last Review Date: 03/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory
More informationIron and Chronic Inflammation. in Obese and Lean Men with Colon Cancer: The Link with Hepcidin
Iron and Chronic Inflammation in Obese and Lean Men with Colon Cancer: The Link with Hepcidin BY CENK KAAN PUSATCIOGLU B.S., University of Illinois at Urbana-Champaign, 2007 THESIS Submitted as partial
More informationNext-Generation Biomarkers for Iron Status
Applications/End Users Baetge EE, Dhawan A, Prentice AM (eds): Next-Generation Nutritional Biomarkers to Guide Better Health Care. Nestlé Nutr Inst Workshop Ser, vol 84, pp 59 69, (DOI: 10.1159/000436955)
More informationShaofu Ma 1), Yoshitaka Koshino 2), Satoko Yamamoto 1), Takeo Shimasaki 1), NaohisaTomosugi 1)
J Kanazawa Med Univ 41 25 31, 2016 Rapid Increase in Serum Iron Level After Oral Iron Intake as an Indicator of Duodenal Iron Absorption and Inverse Regulation of Iron Absorption by Hepcidin Expression
More informationIs the acronym IRIDA acceptable for slow responders to iron in the presence of TMPRSS6 mutations?
The Turkish Journal of Pediatrics 2013; 55: 479-484 Original Is the acronym IRIDA acceptable for slow responders to iron in the presence of TMPRSS6 mutations? Ebru Yılmaz-Keskin 1, Ertan Sal 1, Luigia
More information3/22/2017. Ironing Out the Details: A Review of Iron Deficiency Anemia and Safety Update for Iron Replacement Products. Disclosure.
Ironing Out the Details: A Review of Iron Deficiency Anemia and Safety Update for Iron Replacement Products Kyle Hampson, Pharm.D., CNSC Clinical Pharmacy Specialist, Nutrition Support and Intestinal Rehabilitation
More informationMetabolic Liver Disease: What s New in Diagnosis and Therapy?
Metabolic Liver Disease: What s New in Diagnosis and Therapy? Bruce R. Bacon, M.D. James F. King M.D. Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and Hepatology
More informationThe Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders
UPDATES ON DISORDERS OF IRON UTILIZATION AND DISTRIBUTION The Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders Tomas Ganz 1 and Elizabeta Nemeth 1 1 Department
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationthe only oral supplement so quick and effective:
The Product the only oral supplement so quick and effective: 30 days to increase ferritinemia and syderemia to +50% [90-120 days with common oral supplementation with iron]. After 1 week the subject will
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationStacey Melquist #AHA16
Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein(a) Monday, November 14, 2016
More informationReview. Laboratory use of hepcidin in renal transplant recipients. Introduction. Lucija Šimetić *1,2, Lada Zibar 3,4
Review Laboratory use of hepcidin in renal transplant recipients Lucija Šimetić *1,2, Lada Zibar 3,4 1 Department of Clinical Laboratory Diagnostics, Osijek University Hospital, Osijek, Croatia 2 Department
More informationLVHN Scholarly Works. Lehigh Valley Health Network. Nelson Kopyt DO, FASN, FACP Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Efficacy and Safety of Oral Ferric Maltol (FM) in Treating Iron-Deficiency Anemia (IDA) in Patients with Chronic Kidney Disease
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important Reminder at
More informationBONE MARROW PERIPHERAL BLOOD Erythrocyte
None Disclaimer Objectives Define anemia Classify anemia according to pathogenesis & clinical significance Understand Red cell indices Relate the red cell indices with type of anemia Interpret CBC to approach
More informationUniversity of Groningen. Iron status and heart failure Klip, IJsbrand Thomas
University of Groningen Iron status and heart failure Klip, IJsbrand Thomas IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationIron Deficiency, Depression, and Other Affective Disorders in Female State Fair Attendees
Iron Deficiency, Depression, and Other Affective Disorders in Female State Fair Attendees A thesis submitted to the faculty of the University of Minnesota by Kathleen Price In partial fulfillment of the
More informationResearch and Development
SNP Frequencies in SLC11A2, HFE, TMPRSS6, and TF and their Association with the Indicators of Blood Iron Status and Concentration in Pregnant Filipino Women Vanessa Joy A. Timoteo a, Jacus S. Nacis a,
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationAnemia in -thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression
BRIEF REPORTS Anemia in -thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression Emilie Camberlein, 1 Giuliana Zanninelli,
More informationReducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice
Related Commentary, page 1424 Research article Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice Shuling Guo, 1 Carla Casu, 2 Sara Gardenghi, 2 Sheri Booten, 1 Mariam Aghajan, 1 Raechel
More informationINTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED
INTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED Rationale for Combining Iron & Vit-D Vit D deficiency and Iron deficiency Anaemia the two most menacing disorders - are inter-related
More informationReview Article Unexplained Aspects of Anemia of Inflammation
Advances in Hematology Volume 2010, Article ID 508739, 5 pages doi:10.1155/2010/508739 Review Article Unexplained Aspects of Anemia of Inflammation Elizabeth A. Price 1, 2 and Stanley L. Schrier 1 1 Department
More informationSerum hepcidin levels and iron parameters in children with iron deficiency
VOLUME 47 ㆍ NUMBER 4 ㆍ December 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Serum hepcidin levels and iron parameters in children with iron deficiency Hyoung Soo Choi 1, Sang Hoon Song 2, Jae
More informationAssessing Iron Status in CKD Patients: New Laboratory Parameters
14 Assessing Iron Status in CKD Patients: New Laboratory Parameters Eloísa Urrechaga 1, Luís Borque 2 and Jesús F. Escanero 2 1 Laboratory, Hospital Galdakao, Usansolo Galdakao, Vizcaya 2 Department of
More informationBCH 471. Experiment (5) Hemoglobin Estimation, Erythrocyte Sedimentation Rate (ESR) and Hematocrit (HCT)
BCH 471 Experiment (5) Hemoglobin Estimation, Erythrocyte Sedimentation Rate (ESR) and Hematocrit (HCT) Objectives Quantitative determination of hemoglobin in a blood sample. Determination of erythrocyte
More informationSerum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation
The Journal of International Medical Research 2011; 39: 1961 1967 Serum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation Y XU, XQ DING, JZ ZOU, ZH LIU, SH JIANG AND
More informationINTERNAL MEDICINE - PEDIATRICS
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 2 INTERNAL MEDICINE - PEDIATRICS UPDATES NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY A.L. Strat
More informationRéunion annuelle de pathologie digestive. Iron Metabolism
Réunion annuelle de pathologie digestive Hopital Cochin-Hôtel Dieu Iron Metabolism 3 Février 2012 Sophie Vaulont Iron metabolism endosome steap IRP Pigeon et ferritin al., 2001, JBC, 276, 7811-7819 use
More informationHepcidin and iron regulation, 10 years later
Review article Hepcidin and iron regulation, 10 years later Tomas Ganz 1 1 Departments of Medicine and Pathology, David Geffen School of Medicine at UCLA, Los Angeles, CA Introduction Under evolutionary
More informationHepcidin as a Novel Biomarker of Congestive Hepatopathy in Advanced Heart Failure Patients
Christine J. Chung Doris Duke Clinical Research Fellow 7/7/2011 Hepcidin as a Novel Biomarker of Congestive Hepatopathy in Advanced Heart Failure Patients I. Study Purpose and Rationale Background: Heart
More informationIron deficiency in heart failure
Iron deficiency in heart failure Piotr Ponikowski, MD, PhD, FESC Department of Heart Diseases, Wroclaw Medical University Centre for Heart Diseases, Military Hospital, Wroclaw, Poland Objectives Importance
More information